The health and safety of our employees, patients, customers and communities is our top priority. Read about our response to COVID-19

Inspire Medical Systems to Present at Three Upcoming Investor Conferences

Download as PDF

MINNEAPOLIS, Nov. 10, 2015 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc., announced today that Tim Herbert, President and Chief Executive Officer, will provide a corporate update at three healthcare investor conferences in November and December.

Stifel 2015 Healthcare Conference
Date: Wednesday, November 18, 2015
Time: 11:45am Eastern Time
Location: The New York Palace Hotel

Canaccord Genuity 2015 Medical Technology & Diagnostics Conference
Date: Thursday, November 19, 2015
Time: 2:20pm Eastern Time
Location: The Westin New York Grand Central Hotel

Piper Jaffray 27th Annual Healthcare Conference
Date: Wednesday, December 2, 2015
Time: 11:10am Eastern Time
Location: The New York Palace Hotel

About Inspire Therapy
Untreated Obstructive Sleep Apnea (OSA) can have devastating effects on heart and brain health, impair
quality of life, and increase accident risk. Inspire Upper Airway Stimulation (UAS) therapy is an FDA-
approved treatment for some people with moderate to severe OSA who are unable to tolerate or get
relief from CPAP. In contrast to CPAP, Inspire therapy is implanted inside the body and works with a
patient’s natural breathing process. Controlled by the patient sleep remote, the system includes a
breathing sensor and a stimulation lead powered by a small battery. During sleep, the system senses
breathing patterns and delivers mild stimulation to the tongue and other soft tissues of the throat to
keep the airway open. Inspire therapy is currently available at more than 60 leading medical centers
across the United States and Europe.

About Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc., based in Minneapolis, Minn., was incorporated in 2007 with the sole
purpose of developing a safe, effective and well-accepted therapy to help those OSA patients who are
unable to tolerate or get relief from CPAP. Inspire therapy is the world’s first implantable FDA-approved
neurostimulation system for the treatment of OSA. The Company is privately held and investors include
Aperture Venture Partners, GDN Holdings, Johnson & Johnson, Kleiner Perkins Caufield & Byers,
Medtronic, OrbiMed Advisors, Synergy Life Science Partners, TGap Ventures and US Venture Partners.

For more information, visit

Investor contact: Bob Yedid, LifeSci Advisors